Safety and Efficacy of IB-FOLFIRI in BRAF V600E-Mutant Metastatic Colorectal Cancer

计划入组 20 人 · 首次发布于 2025 年 9 月 2 日

First-line FOLFOXIRI Plus Bevacizumab in BRAF Mutant Metastatic Colorectal Cancer

计划入组 15 人 · 首次发布于 2011 年 9 月 21 日

Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer

计划入组 165 人 · 首次发布于 2023 年 8 月 23 日

BRAF-V600E degrader

Oncolipin-IT Colorectal Cancer

Deflexifol

Austrian Breast & Colorectal Cancer Study Group

Austria

BORDEAUX COLORECTAL INSTITUTE ACADEMY

France

Cardiff Oncology

United States

Pfizer's BRAFTOVI Combination Therapy Halves Death Risk in BRAF-Mutant Metastatic Colorectal Cancer

FDA Grants Breakthrough Therapy Designation to Novel Triplet Combination for BRAF-Mutant Metastatic Colorectal Cancer

Pierre Fabre Advances Two Phase II Trials of Encorafenib in Chinese Patients with BRAF V600E Mutations